Richard Law
Stock Analyst at Goldman Sachs
(2.84)
# 1,557
Out of 5,182 analysts
80
Total ratings
34.21%
Success rate
3.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Maintains: Buy | $36 → $31 | $13.61 | +127.77% | 6 | Apr 7, 2026 | |
| BCAX Bicara Therapeutics | Maintains: Neutral | $14 → $16 | $21.92 | -27.01% | 1 | Mar 31, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $38 → $27 | $14.59 | +85.06% | 8 | Mar 18, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Neutral | $65 → $95 | $101.21 | -6.14% | 1 | Mar 3, 2026 | |
| RCKT Rocket Pharmaceuticals | Maintains: Sell | $2 → $3 | $3.43 | -12.54% | 4 | Mar 2, 2026 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $30 → $34 | $33.23 | +2.32% | 4 | Mar 2, 2026 | |
| MLTX MoonLake Immunotherapeutics | Downgrades: Sell | $8 → $10 | $16.66 | -39.98% | 5 | Jan 15, 2026 | |
| RCUS Arcus Biosciences | Upgrades: Buy | $16 → $28 | $24.80 | +12.90% | 1 | Jan 13, 2026 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $67 | $38.15 | +75.62% | 2 | Jan 12, 2026 | |
| NUVL Nuvalent | Maintains: Buy | $120 → $135 | $101.94 | +32.43% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $29 | $23.32 | +24.36% | 2 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $52 | $25.89 | +100.85% | 7 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $4 → $3 | $7.70 | -61.04% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $30 | $32.39 | -7.38% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 | $19.01 | -42.14% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $30.56 | +53.80% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $52.06 | +21.01% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $83.85 | -55.87% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $13.20 | +475.76% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $3.06 | +357.52% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $10.22 | +496.87% | 4 | May 8, 2023 |
Viridian Therapeutics
Apr 7, 2026
Maintains: Buy
Price Target: $36 → $31
Current: $13.61
Upside: +127.77%
Bicara Therapeutics
Mar 31, 2026
Maintains: Neutral
Price Target: $14 → $16
Current: $21.92
Upside: -27.01%
Olema Pharmaceuticals
Mar 18, 2026
Maintains: Buy
Price Target: $38 → $27
Current: $14.59
Upside: +85.06%
Protagonist Therapeutics
Mar 3, 2026
Maintains: Neutral
Price Target: $65 → $95
Current: $101.21
Upside: -6.14%
Rocket Pharmaceuticals
Mar 2, 2026
Maintains: Sell
Price Target: $2 → $3
Current: $3.43
Upside: -12.54%
Celldex Therapeutics
Mar 2, 2026
Maintains: Neutral
Price Target: $30 → $34
Current: $33.23
Upside: +2.32%
MoonLake Immunotherapeutics
Jan 15, 2026
Downgrades: Sell
Price Target: $8 → $10
Current: $16.66
Upside: -39.98%
Arcus Biosciences
Jan 13, 2026
Upgrades: Buy
Price Target: $16 → $28
Current: $24.80
Upside: +12.90%
Crinetics Pharmaceuticals
Jan 12, 2026
Upgrades: Buy
Price Target: $67
Current: $38.15
Upside: +75.62%
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $120 → $135
Current: $101.94
Upside: +32.43%
Oct 30, 2025
Maintains: Neutral
Price Target: $19 → $29
Current: $23.32
Upside: +24.36%
Sep 9, 2025
Maintains: Buy
Price Target: $32 → $52
Current: $25.89
Upside: +100.85%
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $7.70
Upside: -61.04%
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $32.39
Upside: -7.38%
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $19.01
Upside: -42.14%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $30.56
Upside: +53.80%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $52.06
Upside: +21.01%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $83.85
Upside: -55.87%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $13.20
Upside: +475.76%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $3.06
Upside: +357.52%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $10.22
Upside: +496.87%